Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
PHASE3CompletedINTERVENTIONAL
Enrollment
130
Participants
Timeline
Start Date
July 5, 2013
Primary Completion Date
April 2, 2015
Study Completion Date
April 14, 2015
Conditions
GlaucomaOcular Hypertension
Interventions
DRUG
Latanoprostene bunod
Trial Locations (1)
08807
Bausch & Lomb Incorporated, Bridgewater
All Listed Sponsors
lead
Bausch & Lomb Incorporated
INDUSTRY
NCT01895972 - Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT | Biotech Hunter | Biotech Hunter